Search Results - "Ginos, Brenda"

Feasibility study of online yoga for symptom management in patients with myeloproliferative neoplasms by Huberty, Jennifer, Eckert, Ryan, Gowin, Krisstina, Mitchell, Jules, Dueck, Amylou C, Ginos, Brenda F, Larkey, Linda, Mesa, Ruben

Get full text

Long-Term Toxic Effects, Swallow Function, and Quality of Life on MC1273: A Phase 2 Study of Dose De-escalation for Adjuvant Chemoradiation in Human Papillomavirus-Positive Oropharyngeal Cancer by Price, Katharine, Van Abel, Kathryn M., Moore, Eric J., Patel, Samir H., Hinni, Michael L., Chintakuntlawar, Ashish V., Graner, Darlene, Neben-Wittich, Michelle, Garces, Yolanda I., Price, Daniel L., Janus, Jeffrey R., Foster, Nathan R., Ginos, Brenda F., Foote, Robert L., Ma, Daniel

“…Patients with human papillomavirus oropharyngeal cancer are highly curable but risk significant long-term toxic effects with standard therapy. This study…”
Get full text

Identification of meaningful individual-level change thresholds for worsening on the patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE®) by Lee, Minji K., Mitchell, Sandra A., Basch, Ethan, Mazza, Gina L., Langlais, Blake T., Thanarajasingam, Gita, Ginos, Brenda F., Rogak, Lauren, Meek, Eric A., Jansen, Jennifer, Deal, Allison M., Carr, Philip, Blinder, Victoria S., Jonsson, Mattias, Mody, Gita N., Mendoza, Tito R., Bennett, Antonia V., Schrag, Deborah, Dueck, Amylou C.

“…We derived meaningful individual-level change thresholds for worsening in selected patient-reported outcomes version of the common terminology criteria for…”
Get full text

Randomized Phase II Study of Two Doses of Pixantrone in Patients with Metastatic Breast Cancer (NCCTG N1031, Alliance) by Sideras, Kostandinos, Hillman, David W, Giridhar, Karthik, Ginos, Brenda F, Tenglin, Richard C, Liu, Heshan, Chen, Beiyun, Tan, Winston, Gross, Gerald G, Mowat, Rex B, Dueck, Amylou C, Perez, Edith A, Moreno-Aspitia, Alvaro

“…Anthracycline use in metastatic breast cancer (MBC) is hindered by cumulative exposure limits and risk of cardiotoxicity. Pixantrone, a novel…”
Get full text

Blue light photodynamic therapy with 5-aminolevulinic acid in refractory mycosis fungoides: A prospective, open-label study by Severson, Kevin J., Cumsky, Helen J.L., Brumfiel, Caitlin M., Janeczek, Monica C., Ginos, Brenda F., Kosiorek, Heidi E., Besch-Stokes, Jake, Patel, Meera H., Rule, William G., DiCaudo, David J., Rosenthal, Allison C., Pittelkow, Mark R., Mangold, Aaron R.

Get full text

Missing data strategies for the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) in Alliance A091105 and COMET-2 by Mazza, Gina L., Petersen, Molly M., Ginos, Brenda, Langlais, Blake T., Heon, Narre, Gounder, Mrinal M., Mahoney, Michelle R., Zoroufy, Alexander J., Schwartz, Gary K., Rogak, Lauren J., Thanarajasingam, Gita, Basch, Ethan, Dueck, Amylou C.

“…Purpose Missing scores complicate analysis of the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) because…”
Get full text

Statistical properties of items and summary scores from the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE ® ) in a diverse cancer sample by Mead-Harvey, Carolyn, Basch, Ethan, Rogak, Lauren J, Langlais, Blake T, Thanarajasingam, Gita, Ginos, Brenda F, Lee, Minji K, Yee, Claire, Mitchell, Sandra A, Minasian, Lori M, Mendoza, Tito R, Bennett, Antonia V, Schrag, Deborah, Dueck, Amylou C, Mazza, Gina L

“…The Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE ) was developed to capture symptomatic adverse events…”
Get full text

Correction to: Missing data strategies for the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) in Alliance A091105 and COMET-2 by Mazza, Gina L., Petersen, Molly M., Ginos, Brenda, Langlais, Blake T., Heon, Narre, Gounder, Mrinal M., Mahoney, Michelle R., Zoroufy, Alexander J., Schwartz, Gary K., Rogak, Lauren J., Thanarajasingam, Gita, Basch, Ethan, Dueck, Amylou C.

Get full text

Predictors of Progression in Barrett's Esophagus with Low-Grade Dysplasia: Results from a Multicenter Prospective BE Registry by Krishnamoorthi, Rajesh, Lewis, Jason T, Krishna, Murli, Crews, Nicholas J, Johnson, Michele L, Dierkhising, Ross A, Ginos, Brenda F, Wang, Kenneth K, Wolfsen, Herbert C, Fleischer, David E, Ramirez, Francisco C, Buttar, Navtej S, Katzka, David A, Iyer, Prasad G

“…Low-grade dysplasia (LGD) is a risk factor for progression in Barrett's esophagus (BE). Progression estimates however vary and predictors of progression are…”
Get full text

Phase II trial of nab‐paclitaxel in patients with relapsed or refractory multiple myeloma by Jain, Tania, Dueck, Amylou C., Kosiorek, Heidi e., Ginos, Brenda F., Mayo, Angela, Reeder, Craig B., Chesi, Marta, Mikhael, Joseph, Keith Stewart, A., Leif Bergsagel, P., Fonseca, Rafael

Get full text

A phase 2 study of rituximab, cyclophosphamide, bortezomib and dexamethasone (R-CyBorD) in relapsed low grade and mantle cell lymphoma by Sonbol, Mohamad Bassam, Hilal, Talal, Dueck, Amylou C., Rosenthal, Allison C., Conley, Christopher R., Kosiorek, Heidi E., Ginos, Brenda F., Gano, Katherine M., Nichols, Craig S., Leis, Jose F., Johnston, Patrick B., Habermann, Thomas M., Northfelt, Donald W., Bergsagel, Peter Leif, Inwards, David J., Witzig, Thomas E., Ansell, Stephen M., Reeder, Craig B.

“…In this phase 2 trial, we sought to evaluate the efficacy and safety of rituximab, cyclophosphamide, bortezomib, and dexamethasone (R-CyBorD) in patients with…”
Get full text

A Novel Combination of the mTORC1 Inhibitor Everolimus and the Immunomodulatory Drug Lenalidomide Produces Durable Responses in Patients With Heavily Pretreated Relapsed Lymphoma by Padrnos, Leslie, Ernst, Brenda, Dueck, Amylou C., Kosiorek, Heidi E., Ginos, Brenda F., Toro, Angela, Johnston, Patrick B., Habermann, Thomas M., Leis, Jose F., Mikhael, Joseph R., Nowakowski, Grzegorz S., Colgan, Joseph, Porrata, Luis, Ansell, Stephen M., Witzig, Thomas E., Reeder, Craig

“…Relapsed and refractory lymphoproliferative neoplasms have a significant need for novel therapeutic options. A phase I/II trial using a combination therapy of…”
Get full text

Patient-Reported Outcomes During and After Treatment for Locally Advanced Rectal Cancer in the PROSPECT Trial (Alliance N1048) by Basch, Ethan, Dueck, Amylou C, Mitchell, Sandra A, Mamon, Harvey, Weiser, Martin, Saltz, Leonard, Gollub, Marc, Rogak, Lauren, Ginos, Brenda, Mazza, Gina L, Colgrove, Brian, Chang, George, Minasian, Lori, Denicoff, Andrea, Thanarajasingam, Gita, Musher, Benjamin, George, Thomas, Venook, Alan, Farma, Jeffrey, O'Reilly, Eileen, Meyerhardt, Jeffrey A, Shi, Qian, Schrag, Deborah

“…The standard of care for locally advanced rectal cancer in North America is neoadjuvant pelvic chemoradiation with fluorouracil (5FUCRT). Neoadjuvant…”
Get full text

Effect of Electronic Symptom Monitoring on Patient-Reported Outcomes Among Patients With Metastatic Cancer: A Randomized Clinical Trial by Basch, Ethan, Schrag, Deborah, Henson, Sydney, Jansen, Jennifer, Ginos, Brenda, Stover, Angela M, Carr, Philip, Spears, Patricia A, Jonsson, Mattias, Deal, Allison M, Bennett, Antonia V, Thanarajasingam, Gita, Rogak, Lauren J, Reeve, Bryce B, Snyder, Claire, Bruner, Deborah, Cella, David, Kottschade, Lisa A, Perlmutter, Jane, Geoghegan, Cindy, Samuel-Ryals, Cleo A, Given, Barbara, Mazza, Gina L, Miller, Robert, Strasser, Jon F, Zylla, Dylan M, Weiss, Anna, Blinder, Victoria S, Dueck, Amylou C

“…IMPORTANCE: Electronic systems that facilitate patient-reported outcome (PRO) surveys for patients with cancer may detect symptoms early and prompt clinicians…”
Get full text

Phase II Evaluation of Aggressive Dose De-Escalation for Adjuvant Chemoradiotherapy in Human Papillomavirus-Associated Oropharynx Squamous Cell Carcinoma by Ma, Daniel J, Price, Katharine A, Moore, Eric J, Patel, Samir H, Hinni, Michael L, Garcia, Joaquin J, Graner, Darlene E, Foster, Nathan R, Ginos, Brenda, Neben-Wittich, Michelle, Garces, Yolanda I, Chintakuntlawar, Ashish V, Price, Daniel L, Olsen, Kerry D, Van Abel, Kathryn M, Kasperbauer, Jan L, Janus, Jeffrey R, Waddle, Mark, Miller, Robert, Shiraishi, Satomi, Foote, Robert L

“…The purpose of this study was to determine if dose de-escalation from 60 to 66 Gy to 30 to 36 Gy of adjuvant radiotherapy (RT) for selected patients with human…”
Get full text

Phase I Trial of Systemic Administration of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and Human Interferon, in Patients with Relapsed or Refractory Multiple Myeloma, Lymphomas, or Histiocytic/Dendritic Cell Neoplasms by Bennani, N. Nora, Cook, Joselle, Geyer, Susan M., Ginos, Brenda F, Zhang, Lianwen, Munoz, Javier, Broski, Stephen, Russell, Stephen, Peng, Kah-Whye, Lacy, Martha

“…Background: Oncolytic virotherapy, an innovative immunomodulatory therapeutic approach, is currently being investigated for its potential in treating relapsed…”
Get full text

Financial Toxicity Monitoring in a Randomized Controlled Trial of Patient-Reported Outcomes During Cancer Treatment (Alliance AFT-39) by Blinder, Victoria S, Deal, Allison M, Ginos, Brenda, Jansen, Jennifer, Dueck, Amylou C, Mazza, Gina L, Henson, Sydney, Carr, Philip, Rogak, Lauren J, Weiss, Anna, Rapperport, Anna, Jonsson, Mattias, Spears, Patricia A, Cella, David, Gany, Francesca, Schrag, Deborah, Basch, Ethan

“…Financial toxicity (FT) affects 20% of cancer survivors and is associated with poor clinical outcomes. No large-scale programs have been implemented to…”
Get full text

Preliminary pharmacokinetic and safety data after a single intravenous infusion of Voyager-V1 (VV1, VSV-IFNβ-NIS) oncolytic virus in patients with relapsed refractory hematologic malignancies by Peng, Kah Whye, Remick, Adam, Bennani, Nabila Nora, Cook, Joselle, Zhang, Lianwen, Witzig, Thomas E., Munoz, Javier, Broski, Stephen M, Geyer, Susan Michelle, Ginos, Brenda F., Russell, Luke, Bexon, Alice Susannah, Russell, Stephen J., Lacy, Martha

“…e14594 Background: Voyager-V1 (VV1) is an oncolytic vesicular stomatitis virus engineered to express interferon beta (IFNβ) to boost cellular antitumor…”
Get full text

Systemic VSV-IFNβ-NIS oncolytic virotherapy in patients with relapsed refractory T-cell lymphoma by Bennani, Nabila Nora, Cook, Joselle, Peng, Kah-Whye, Geyer, Susan Michelle, Ginos, Brenda F., Zhang, Lianwen, Macapagal, Sharina C., Witzig, Thomas E., Munoz, Javier, Broski, Stephen M, Russell, Stephen J., Lacy, Martha

“…7530 Background: Oncolytic virotherapy is a novel immunomodulatory therapeutic approach currently under study for relapsed refractory (R/R) hematologic…”
Get full text

A randomized controlled trial of routine financial toxicity screening via electronic patient-reported outcomes (AFT-39) by Blinder, Victoria Susana, Deal, Allison Mary, Ginos, Brenda F., Jansen, Jennifer, Dueck, Amylou C., Mazza, Gina L., Henson, Sydney, Carr, Philip M, Rogak, Lauren J., Weiss, Anna, Rapperport, Anna, Spears, Patricia, Gany, Francesca, Schrag, Deborah, Basch, Ethan

“…180 Background: Financial toxicity affects 20% of cancer survivors and is associated with decreased treatment adherence and poor clinical outcomes. No…”
Get full text